Why is "Transthyretin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-08 02:13:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Transthyretin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-08 and was most recently seen on 2026-08-08.
Wikipedia Overview
Transthyretin (TTR or TBPA) is a transport protein in the plasma and cerebrospinal fluid that transports the thyroid hormone thyroxine (T4) and retinol to the liver. This is how transthyretin gained its name: transports thyroxine and retinol. The liver secretes TTR into the blood, and the choroid plexus secretes TTR into the cerebrospinal fluid.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions - The Lancet
-
Prognostic Significance of Low Alanine Aminotransferase in Transthyretin Amyloid Cardiomyopathy - JACC Journals
-
Managing Cardiac Amyloidosis in a Rural Cardiology Practice: Bridging Gaps in Specialized Evaluation and Disease-Modifying Treatment - Cureus
-
Cryo-EM structures of biopsy-derived TTR fibrils in hereditary transthyretin amyloidosis - Nature
-
Health Care Resource Utilization in Transthyretin Amyloid Cardiomyopathy Compared With Non‐amyloid Heart Failure and the General Population - American Heart Association Journals
-
ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM - Fierce Pharma
-
Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report - Frontiers
-
Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy - medicalxpress.com
-
Prognostic Significance of Low Alanine Aminotransferase in Transthyretin Amyloid Cardiomyopathy - JACC Journals
-
Structures of dye-bound transthyretin amyloid fibrils from abdominal fat biopsies - Nature
-
Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Complete Heart Block Unmasking Transthyretin Cardiac Amyloidosis: A Multimodality Imaging Case Report - Cureus
-
Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy - JACC Journals
-
Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosis - Nature
-
Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States - American Heart Association Journals
-
Phenomenological model of transthyretin stabilization - Nature
-
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis - Nature
-
Three‐Dimensional Visualization and Proteomic Analysis of Human Cardiac Transthyretin Amyloidosis Tissue Reveals Microangiopathy and Capillary Occlusion - American Heart Association Journals
-
Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy - Nature
-
Levels and instability of transthyretin and correlations with core biomarkers in Alzheimer’s disease - Nature
-
Wild-Type Transthyretin Cardiac Amyloidosis Presenting As Progressive Heart Failure and Conduction Disease Despite Guideline-Directed Medical Therapy - Cureus
-
Efficacy of Suppression of Serum Transthyretin With Patisiran and Vutrisiran in Variant ATTR Amyloidosis: An Observational Crossover Study - American Heart Association Journals
-
Synovial Biopsy as a Diagnostic Clue for Transthyretin Amyloidosis With the Rare Tyr98Phe Variant Presenting Predominantly With Severe Musculoskeletal Manifestations - Cureus
-
Transthyretin Cardiac Amyloidosis in an Older Athlete - Cureus
-
Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM - Medscape
-
Phase 3 Eplontersen Trial Results Disappoint - Medscape
-
Correlation between neuropathy severity and neurofilament light chain levels in Brazilian patients with hereditary transthyretin amyloidosis - Nature
-
Right Atrial Function as a Novel Predictor for New‐Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy - American Heart Association Journals
-
Reappraising Left Ventricular Wall Thickness in Developing Clinical Suspicion for Transthyretin Cardiac Amyloidosis - JACC Journals
-
Global Longitudinal Strain for Prognostic Staging in Wild-Type Transthyretin Cardiac Amyloidosis - American Heart Association Journals
-
Investigation of Acoramidis-based ionic liquids as potential stabilizers of transthyretin using DFT calculations, molecular docking, and ADMET studies - Nature
-
Diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM)? Here's what to know about this rare heart condition - Mayo Clinic Press
-
The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM: - JACC Journals
-
A Return to Munich: Reflecting on Eight Years of Progress in ATTR-CM - Pfizer
-
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges - ajmc.com
-
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis - Nature
-
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients - Wiley Online Library
-
Targeting transthyretin deposition in lumbar spinal stenosis: a mechanistic rationale for tafamidis - Frontiers
-
Spotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection - Pfizer
-
Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early‐Onset Amyloid Cardiomyopathy - American Heart Association Journals
-
Serum transthyretin combined with first trimester uterine artery doppler ultrasound for preeclampsia prediction in singleton pregnancies: a prospective observational study - Nature
-
Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags - Nature
-
Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies - CGTLive®
-
Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM - ajmc.com
-
Long-Term Hemodynamic Stabilization With TTR-Stabilizing Therapy and Pressure-Guided Management in ATTR Cardiomyopathy - JACC Journals
-
Understanding the heart disease aspect of transthyretin amyloid cardiomyopathy (ATTR-CM) - Mayo Clinic Press
-
p.Asp58Val Hereditary Transthyretin Amyloidosis: A Case Report and Literature Review - Cureus
-
Catheter Ablation and Device Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Review of Non-Pharmacological Therapy - Wiley Online Library
-
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy? - American Heart Association Journals
-
Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy - JACC Journals
-
How science and collaboration led to a breakthrough in transthyretin cardiac amyloidosis - STAT
-
Anti-Fibril Depleters: The Dawn of a New Treatment Era in Transthyretin Amyloid Cardiomyopathy? - American Heart Association Journals
-
Tc]Tc-Pyrophosphate SPECT/CT Images in Transthyretin Cardiac Amyloidosis: A Pilot Study - Journal of Nuclear Medicine
-
Outpatient Worsening Heart Failure Predicts Mortality in Patients With ATTR-CM - ajmc.com
-
New method reveals how mutations drive transthyretin amyloidosis and guides precision drug design - Phys.org
-
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE - CGTLive®
-
Transthyretin Amyloidosis Treatment Market Size to Reach - GlobeNewswire
-
Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug - Fierce Biotech
-
CARDIO-TTRansform trial investigating eplontersen fails to meet primary efficacy endpoint - News-Medical
-
Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients - Nature
-
Cas3 Generates Large Deletions in Amyloidosis Model - CRISPR Medicine News
-
Cardiac amyloidosis in the spotlight at Heart Failure 2026 - Cardiovascular Business
-
6 Sneaky Signs You Have ATTR-CM - HealthCentral
-
Trends in diagnostic testing in Medicare patients with wild-type transthyretin amyloid cardiomyopathy - Frontiers
-
Vitamin A: What you should know about supplements and ATTR-CM treatments - Mayo Clinic Press
-
Mechanistic Roles of Transthyretin Silencers and Stabilizers in ATTR-CM - HCPLive
-
New data suggest ATTR-CM therapy may help reverse heart damage - Amyloidosis News Today
-
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM - Fierce Biotech
-
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
-
Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data - Wiley Online Library
-
The left ventricular mechanical dispersion as a marker of disease severity in transthyretin cardiac amyloidosis - Nature
-
Residual Graft Pathology During CABG as a Minimally Invasive Diagnostic Pathway for Transthyretin Amyloidosis - JACC Journals
-
DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific Markets - Yahoo Finance
-
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy - BioSpace
-
Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy - AstraZeneca
-
Advanced Cardiac MRI Identifies Early Signs of Transthyretin Amyloidosis - ajmc.com
-
Single-Dose Nexiguran Ziclumeran (CRISPR-Cas9) Gene Editing Achieves Sustained TTR Reduction in Hereditary Transthyretin Amyloidosis with Polyneuropathy - Vera Health
-
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy - BioSpace
-
Clinical Burden and Barriers to Early Diagnosis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - HCPLive
-
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran fo - Alnylam
-
Long-Term Safety of Vutrisiran Confirmed in ATTR Amyloidosis Analysis - ajmc.com
-
ATTR-CM in Black Patients: Risks, Symptoms, and Treatment Options - HealthCentral
-
Integrative structural profiling and ligand optimisation across the transthyretin mutational landscape - Nature
-
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM - Business Wire
-
Transthyretin Cardiac Amyloidosis With Reduced Ejection Fraction in a 47-Year-Old Man: An Unusual Presentation - Cureus
-
New Proposed Criteria For Monitoring Disease Progression in ATTR-CM - American College of Cardiology
-
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics
-
5 companies advancing ATTR assets in the wake of Wainua’s fail - BioSpace
-
AF in ATTR-CA: Prevalence, Predictors and Protective Factors - American College of Cardiology
-
What to know about ATTR-CM and treatment options - Managed Healthcare Executive
-
How I Support My Loved One with ATTR-CM: A Personal Story - healthline.com
-
CRISPR-Cas3: A safer gene-editing tool shows promise for transthyretin amyloidosis treatment - News-Medical
-
ATTR-C Treatment Options: medications and lifestyle changes - Verywell Health
-
Updated ATTR-CM Criteria Standardize Disease Progression Monitoring - ajmc.com
-
Coramitug wins FDA fast track status for rare heart condition - Managed Healthcare Executive
-
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A - springermedicine.com
-
AstraZeneca, Ionis drug fails big heart disease study in major setback - BioPharma Dive
-
AI Advances Detection of Transthyretin Cardiac Amyloidosis - emjreviews.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.